REPO4EU

"The future of medicine and the economy isn't about endless expansion; it’s about smarter, more sustainable innovation." Does #DrugRepurposing have the power to shape the #FutureOfMedicine as well as the #FutureEconomy? And how can the #EUfunded initiative REPO4EU contribute to tackling issues around efficiency and circularity in #Medicine and the overall #GlobalEconomy? 💊 📈 🌍 Find out in this article by our Project Coordinator, Harald H.H.W. Schmidt 👇

Enhancing Drug Repurposing in Europe and the World 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐚 𝐭𝐨𝐮𝐜𝐡 𝐛𝐚𝐬𝐞 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐢𝐧 𝐁𝐫𝐮𝐱𝐞𝐥𝐥𝐞𝐬   On October 30, Egnosis participated in the Drug Repurposing Clusters meeting in Brussels, hosted by the European Health and Digital Executive Agency (HaDEA). The event brought together representatives of the REPO4EU and REMEDi4ALL projects, aiming to showcase recent advancements, map synergies and foster collaboration. In her welcoming address, EU project officer Monica Ensini emphasized the significance of the projects and outlined the high expectations for these unique drug repurposing initiatives. Further, the coordinators—Harald H.H.W. Schmidt ⚕️💊 from REPO4EU, Anton Ussi and Donald Lo from REMEDi4ALL—presented a brief status and current advancements of the two projects. As key technology providers in REPO4EU, our colleagues from Egnosis presented the implementation plan for the #drugrepurposing #platform #development. They also shared ideas on how #AI, #ML, #BigData, and #LLMs can enhance the platform's long-term technical sustainability while drawing attention to the impact of the #AIAct on regulatory requirements. In addition to the great networking event, we are truly grateful to have had the opportunity to showcase our IT expertise and share insights with project stakeholders. Congratulations and thanks to all dedicated REPO delegates and project partners for the collaborative efforts! Hermann Mucke, Harald H.H.W. Schmidt ⚕️💊, Emre Guney, Béla Bihari, Stephanie Dawson, Balázs-Attila Orbán, Miriam Simon, Jorika van Duijn-Wiersma, let’s keep our progress thriving! 🔎 Join us on our scientific journey and read the complete article on our website! https://lnkd.in/dZS_jMQ4

💎 What is Diamond Open Access? Free Access for All! 💎 ScienceOpen is proud to support #DiamondOpenAccess through two journals—where authors and readers access content without fees, thanks to EU-funded REPO4EU grant! This model opens doors for researchers in developing countries who often face steep subscription AND publication costs, ensuring their voices and findings are freely shared. Explore the latest research with no paywalls at DrugRxiv and our diamond journals in #DrugRepoCentral, all supporting a more inclusive open science movement. 🌐 🔗 Discover more: DrugRepoCentral https://lnkd.in/eFkHPQcW #OpenAccess #DiamondOpenAccess #ScienceOpen #GlobalResearch 

🌍 REPO4EU 2024: Leading the Future of Drug Repurposing! 🌍 This week, Stephanie Dawson, CEO of ScienceOpen, attended the Horizon Europe Drug Repurposing Cluster meeting in Brussels, where the projects REPO4EU and REMEDi4ALL discussed the newest advances and challenges. ScienceOpen plays a key role in REPO4EU's strong commitment to open science. Explore our DrugRepoCentral publishing portal that incorporates a wide range of open science tools and practices to share the most reliable and open research in drug repurposing. In the group photo, you’ll see Stephanie Dawson, Jorika van Duijn-Wiersma, Emre Guney, Hermann Mucke, Frank Ruwe, Harald H.H.W. Schmidt, Béla Bihari, Balázs-Attila Orbán, Miriam Simon, and Petra Žalud. Stay tuned to learn more about our impact and innovations! 🔗 DrugRepoCentral https://lnkd.in/eFkHPQcW #OpenScience #DrugRepurposing #REPO4EU #ScienceOpen

#ScienceFridays 🔬 Research paper of the week ➡ ‘Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S.’ 🔎 Abstract: Nonprofit organizations and other non-manufacturers have been ramping up efforts to repurpose widely available generic drugs, but they encounter many challenges to obtain regulatory approval in the U.S. The authors in this study propose how non-manufacturers could utilize existing regulatory authorities and pathways to overcome existing hurdles. ✍️ Authors: Devon Crittenden, Raquel Gallagher, Fernanda M., David Fox and Laura Kleiman, PhD. 🏫 Affiliation: Reboot Rx 📄 Published on: Frontiers in Pharmacology (by Frontiers) Find the link to the article on our #DrugRepurposing Research Collection, curated via ScienceOpen 🔗 https://lnkd.in/eCFzeVqP #FutureOfMedicine #OpenScience #NetworkMedicine #PharmaInnovation

📣WE ARE HIRING!!! We are interested in a motivated Technical Assisstant willing to join us for the next 2 years! Previous experience in imaging and histology techniques will be considered although commitment, enthusiasm, and motivation are the only essential requirements!!👩🔬 In case you are interested, contact me: ✍🏻 anaisabel.casasguijarro@uk-essen.de Please, share this information to anyone who might be interested! 🗣️🔈 Looking forward extending our team! #strokeresearch #networkpharmacology #networkmedicine

#ScienceFridays 🔬 Research paper of the week ➡ ‘Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal’ 🔎 Abstract: Many preclinical studies of #Cancer drug repurposing candidates use in vitro drug concentrations too high to have clinical relevance. In this study, researchers analyzed several FDA-approved #CancerDrugs regarding the correlation between the drug inhibitory concentrations 50% (IC50) tested in cancer cell lines and their corresponding peak serum concentration (Cmax) and area under the curve (AUC) reported in #ClinicalStudies of these drugs. ✍️ Authors: Benjamin Robles Bañuelos, Adriana Romo Pérez, Guadalupe Domínguez-Gómez, Alma Chavez Blanco, Aurora Gonzalez Fierro and Alfonso Dueñas González. 🏫 Affiliations: Universidad Nacional Autónoma de México (UNAM) and Instituto Nacional de Cancerología. 📄 Published on: Clinical & Translational Oncology Journal (by Springer Medicine) Find the link to the article on our #DrugRepurposing Research Collection, curated via ScienceOpen 🔗 https://lnkd.in/eKGzYUrk #FutureOfMedicine #OpenScience #Biochemistry #Biomedicine #DrugDiscovery #CancerResearch #CancerTreatment

#DrugRepurposing News 🗞️ Harvard University’s Zitnik Lab, led by Marinka Zitnik, has developed a new AI tool to speed up drug repurposing efforts — and it’s free to use! TxGNN is a groundbreaking artificial intelligence model created to identify drug candidates for #RareDiseases and conditions with no treatments, representing the largest number of diseases that any single #AImodel can handle to date. It has been released as free of charge to encourage clinicians and scientists advance the search for new therapies, particularly for diseases with unmet medical needs. Read the full story on Forbes, by Greg Licholai ⤵️ https://lnkd.in/e3JfnmDz #FutureOfMedicine #FutureOfHealthcare #DrugDiscovery #DrugResearch #AIinMedicine #AIinHealthcare #RareDiseaseResearch #RareDiseases

#ScienceFridays 🔬 Research paper of the week ➡ ‘Targeting AR-positive breast cancer cells via drug repurposing approach’ 🔎 Abstract: Androgen Receptor (AR) is overexpressed in almost all the molecular subtypes of #BreastCancer. Using AR as the target protein in breast cancer cells, researchers in this study searched for potential repurposing options by screening a library of 1293 FDA-approved drugs and assessing their therapeutic efficacy to treat AR-positive breast cancer. ✍️ Authors: Parijat Dutta, Plaboni Sen, Thirukumaran Kandasamy and Siddhartha Sankar Ghosh. 🏫 Affiliations: Dept. of Biosciences and Bioengineering at Indian Institute of Technology, Guwahati and Nanotechnology, IIT Guwahati 📄 Published on: Computational Biology and Chemistry Journal (by Elsevier) Find the link to the article on our #DrugRepurposing Research Collection, curated via ScienceOpen 🔗 https://lnkd.in/eDQujRM6 #FutureOfMedicine #OpenScience #Biosciences #Biomedicine #DrugDiscovery #CancerResearch #CancerTreatment

#REPO4EU Partners in Action 🦾 The next generation of #Bioinformaticians continues making waves across Europe! Our friends from DaiSyBio, the research group based in TUM School of Life Sciences, were recently in the city of Bielefeld for the German Conference on Bioinformatics 2024. Through various poster presentations and talks, they got to showcase their cutting-edge expertise and knowledge in #Biology, #Medicine and #ComputerScience. If you want to find out more about their work, give them a follow on LinkedIn and check out their official page on TUM’s website 👉 https://lnkd.in/d-W6Tn7Q Meet the full REPO4EU team and learn more about how we’re working together to redefine the #FutureOfMedicine by developing a global approach to mechanism-based #DrugRepurposing 💊 https://lnkd.in/djbWvT2S